Previous 10 | Next 10 |
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highl...
BioLineRx to Report 2021 Annual Results on March 16, 2022 Management to hold a conference call at 10:00 a.m. EST PR Newswire TEL AVIV, Israel , March 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceu...
Announcing additional data from a follow-on study based on its Phase 3 GENESIS trial, BioLineRx (BLRX +3.5%) touted the economic benefits of motixafortide, its experimental agent for stem cell mobilization (SCM) The supplemental analysis performed by the Global Health Economics and Outcomes R...
Indonesia Energy (NYSE:INDO) +46%. Imperial Petroleum (NASDAQ:IMPP) +20%. DBV Technologies (NASDAQ:DBVT) +19%. Canaan (NASDAQ:CAN) +18% on Q4 results. Cedar Realty (NYSE:CDR) +14% on acquisition by Wheeler REIT. Eos Energy (NASDAQ:EOSE) +14%. Wheeler Real Estate (NASDAQ:WH...
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization - Results demonstrate highly significant cost benefits of using Motixafortide in combination with G-CSF, versus plerixafor ...
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors - Initial results anticipated in the first half of 2022 PR Newswire TEL AVIV, Israel , Jan. 24, 2022 /...
If you’re looking for penny stocks to buy, there are a few “secret” ways to build your watch list. Over the weekend, we posted an article: 10 Secret Ways To Find The Best Penny Stocks To Buy In 2022 , and the first way to do so was by looking for news. This has beco...
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients - NDA submission on track for H1 2022 PR Newswire TEL AVIV, Israel , Jan. 18, 2022 /PRNewswire/ -- BioLineRx L...
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Ex...
BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) SAB will provide insight and guidance on the Company's immuno-oncology activities and is comprised of recognized leaders in the fields of cancer immunology, intra-tumoral injections and clinical dev...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...